ASCO GU 2024: Subcutaneous nivolumab as effective as IV for renal cell carcinoma with much faster treatment time
Subcutaneous injection of the immunotherapy nivolumab is non-inferior to intravenous delivery and dramatically reduces treatment…
Browsing: Featured
Injectable agents could improve liquid biopsy for cancer detection and monitoring
Scientists have developed two agents, made of therapeutic nanoparticles and antibodies, that could be given…
ASCO GI 2024: New study adds to ambiguity of role of post-operative ctDNA to guide treatment in patients with low-risk, stage IIA colon cancer
The role of ctDNA, or liquid biopsy, as a predictive tool to guide and monitor…
ASCO GI 2024: New immunotherapy combinations for patients with oesophageal cancer
Results from a new phase III study found that combining PD-L1 and TIGIT inhibitors plus…
ASCO GI 2024: Adding immunotherapy-based combination to TACE improves progression-free survival in patients with most common liver cancer
The addition of durvalumab and bevacizumab to TACE significantly improved progression-free survival in patients with…
Unpacking Endometrial Cancer with Professor Linda Mileshkin
Endometrial cancer is the most common gynaecological cancer in Australia and advanced disease and early…
Molecular ‘super-glue’ shows promise of cancer drug discovery platform
Today, St. Jude Children’s Research Hospital scientists published their work on SJ3149, a compound with…
The OJC Meets Chris Booth
The Oncology Network is delighted to share the return of The OJC Meets, sister series of The Oncology…
Blood test distinguishes neuroendocrine subtype of advanced prostate cancer
Like a criminal entering a witness protection program, cancer cells can shed their past and…
Drinkable, carbon monoxide-infused foam enhances effectiveness of experimental cancer therapy
Did smokers do better than non-smokers in a clinical trial for an experimental cancer treatment?…